AzTrials
AzTrials

Attention Deficit Hyperactivity DisorderNCT03411434

Added Value of the Oculomotor and Cognitive Examination in the Management of Patients With ADHD

A study testing Methylphenidate Oral Tablet in people with Attention Deficit Hyperactivity Disorder, run by Centre Hospitalier Rouffach at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

ADHD is a neurodevelopmental disorder characterized by symptoms of inattention and / or hyperactivity-impulsivity that affects nearly 6% of school-aged children and persists into adulthood. More and more studies are interested in biomarkers of this pathology. Read more about this study

Who is it for?
Ages 7 to 50 years
Conditions the study is for
Attention Deficit Hyperactivity Disorder
What is being tested?
Methylphenidate Oral Tablet
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
90 participants
Where
1 siteFrance
Study dates
17 Feb 2014to 31 Dec 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 7 to 50 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • ADHD diagnosis according to DSM-IV-TR criteria
  • Beneficiary of a social security scheme
  • Having undergone an oculomotor examination as part of their usual care
  • Normal neurological examination

Who cannot join

  • Intellectual Disability (IQ < 70)
  • Proven neurological pathology or identified genetic syndrome
  • Vestibular pathology
  • Ear, nose, and throat (ENT) pathology
  • Neuro-ophthalmological pathology uncorrected by corrective glass (<10/10 in binocular vision

Trial locations and contacts

1 site in 1 country.

Fabrice Duval, MD contact

33389787018

f.duval@ch-rouffach.fr

Alexis Erb, MD contact

33389787018

a.erb@ch-rouffach.fr

France1 site, 1 recruiting
  • Centre Hospitalier Rouffach

    Rouffach, Alsace, 68250

    Fabrice Duval, MD, 33389787018, f.duval@ch-rouffach.fr

    Alexis Erb, MD, 33389787018, a.erb@ch-rouffach.fr

    Recruiting

Other trials in France

About this study

Official title: Added Value of the Oculomotor and Cognitive Examination in the Management of Patients With Attention Deficit Disorder With or Without Hyperactivity. Interventional Study to Evaluate Current Care

ADHD is a neurodevelopmental disorder characterized by symptoms of inattention and / or hyperactivity-impulsivity that affects nearly 6% of school-aged children and persists into adulthood. More and more studies are interested in biomarkers of this pathology. The oculomotricity, which allows to highlight deficits motor and attention present in ADHD, is used routinely in the expert centers. In general, the pharmacological treatment of ADHD is associated with a clinical response in approximately 70% of cases. Today, there is no review to predict the individual response to treatment.

Hypotheses The investigators hypothesize that a precise analysis of the oculomotor markers will allow to measure the improvement of the symptomatology of the ADHD disorder following the introduction of the psycho-stimulatory treatment. In other words, the investigators hypothesize that these markers could be a useful aid in patient follow-up by the clinician and allow early identification of responder and non-responder patients.

Read more

Primary objective The main objective of this study is to measure the added value of oculomotor examination in the follow-up of psycho-stimulant-treated ADHD patients.

Main Evaluation Criteria The primary endpoint is oculomotor performance. Parameters analyzed for each saccade are latency, amplitude, duration, average speed, direction.

Secondary Criteria Evaluation (s) Correlations will be established between oculomotor data and scores obtained at the clinical scales assessing ADHD symptoms of inattention and hyperactivity as well as cognitive performance. The data obtained before the introduction of the psycho-stimulant treatment (V0, baseline) will be compared with those obtained after acute administration of methylphenidate (10 mg orally,V1) and during the follow-up visit at 6 months (V2).

Read the detailed description

Type of study and experimental plan:

This is an interventional study designed to evaluate routine care. Number of Necessary Subjects Participants will be stratified by age to control the effect of age. The age groups to be analyzed are: 7-9 vs 10-12 vs. 13-18 versus 19-29 vs 30-40 and 41-50, each with at least 15 participants. total of 90 participants.

  • Study population The patients included in this study are followed in the general psychiatric department of the Rouffach hospital center for attention deficit disorder with or without hyperactivity (ADHD). The study focuses on ADHD patients aged 7 to 50 years, undergoing an oculomotor and cognitive examination before the initiation of psychostimulant therapy with methylphenidate (MPH) (baseline, V0); two weeks later (V1) following a single low dose administration of MPH (10 mg orally given at 8 AM) ; and at 6-month follow-up (V2) when patients are medicated with adequate dose of MPH.
  • Clinical assessments All subjects are evaluated directly by psychiatrists and neuropsychologists who are experts in the field of ADHD and are experienced in the use of standardized or semi-standardized clinical instruments. Clinical investigation allows extensive and standardized evaluation of patients.
  1. Categorical standardized assessment of ADHD symptoms Diagnostic and Statistical Manual (DSM-IV-TR) ADHD Criteria: Subtype: Combined, Inattentive, Hyperactive-Impulsive.
  • In children-adolescents: CONNERS Evaluation Scale for Teachers and Parents: Hetero-Questionnaire for Assessing Behavioral Disorders in ADHD. ADHD Questionnaire: self-assessment questionnaire for children and adolescents with attention difficulties, agitation and behavioral problems allowing the quantification of ADHD symptoms. ADHD Questionnaire: Hetero-evaluation questionnaire for children and adolescents with attention difficulties, agitation and behavioral problems allowing the quantification of ADHD symptoms. This questionnaire is completed by one of the parents.
  • In adults: Adult Self Reporting Scale (ASRS 1.1): self-assessment grid to assess current adult ADHD disorders. Diagnostic Interview for ADHD in adults (DIVA 2.0): semi-structured interview corresponding to the DSM-IV criteria, according to which the diagnosis of ADHD in adults requires the demonstration of symptoms of ADHD both in childhood and at age adult. This scale is composed of 3 parts that apply each to childhood and adulthood: inattention criteria, hyperactivity-impulsivity criteria, age of onset and impaired functioning due to symptoms. Wender Utah Rating Scale (WURS-25): a self-report scale that allows retrospective assessment of the presence of ADHD registry disorders in childhood. World Health Organization Disability Assessment Schedule (WHODAS 2.0): Self-Assessment Scale, to measure pathology-induced disability in daily living during the last 30 days.
  1. Standardized neurocognitive assessment
  • Intellectual level The intellectual level of the patients is assessed using the Wechsler scales: Wechsler Preschool and Primary Scale of Intelligence (WIPPSI) and Wechsler Intelligence Scale for Children (WISC-IV) according to the age of the subject. The variety of tests proposed by the Wechsler Ladders allows to appreciate the level of cognitive development of the child and adolescents. Adults benefit from Adaptation French National Adult Reading Scale (fNART) which aims to estimate the intellectual pre-morbid level. It consists of a series of 40 words of the French language. The patient is asked to read each word aloud whether or not they know the word. It is therefore necessary to deduce the pronunciation of the word in question.
  • Computerized neurocognitive tests o In children up to 10 years KITAP computerized battery: 6 tests of this battery have been selected and are administered in the following order:
  • alert
  • divided attention
  • flexibility
  • go no go
  • distractibility
  • sustained attention o In children from 11 years old/teenagers/adults Computer Battery TAP 2.2: 8 tests of this battery have been selected and are administered in the following order:
  • phasic attention
  • divided attention
  • flexibility
  • incompatibility
  • go no go
  • visual scan
  • working memory
  • sustained attention The total pass of these tests lasts approximately 45 minutes to which are added 5 minutes of explanation and test (s) for each task (5 x 8). Total duration of the TAP battery run: approximately 1h25.
  • Other neurocognitive tests
  • In children:
  • Memory test
  • 15 words of Rey
  • Memory test - figures
  • Dam tests
  1. Standardized assessment of psychiatric comorbidities other than ADHD
  • In children-adolescents: Social Communication Questionnaire S.C.Q - Social Communication Questionnaire): A tool for identifying the manifestations of Autonomic Spectrum Disorders in three main functional areas: social relations, communication and restricted, stereotyped and repetitive behaviors. Hetero-quiz for parents or a person who knows the child well. C.A.S.T The Childhood Asperger Syndrome Test: hetero-questionnaire to assess the manifestations of Asperger syndrome.
  • In adults: Semi-structured psychiatric interview. Questionnaire Mood Disorder Questionnaire (MDQ): self-questionnaire "mood disorders" allowing screening for bipolar disorders
  1. Standardized evaluation of oculomotor behavior Visually guided horizontal and vertical saccade tests: A fixation point is shown in the center of the screen, after a time interval of 200 ms, the center point disappears and a new point appears on the right or left at 20 ° from the initial position. The eyes must move on the new target. Thirty horizontal and 30 vertical saccades are presented Voluntary horizontal saccadic tests: The parameters are identical to those exposed in visually guided saccadic tests except that the central point does not disappear when the second point appears on the right or on the left (top or bottom) at 20 ° from the central point. Thirty horizontal saccades are presented. Anti-saccadic tests: A fixation point is presented in the center of the screen, after an interval of 200ms, the central point disappears and a new point appears on the right or on the left (top or bottom) at 20 ° from the initial position. The eyes must be pointing away from the point. Thirty horizontal saccades are presented. All oculomotor tests last 1 minute. Horizontal and vertical chase tests: A target moves on the screen for about 50 seconds, the eyes must follow the target. The speed of the target varies from 5 ° Reading and Visual Search Tests: A text of 4 lines is presented on the computer screen. The participants must read it in a low voice, the movements of the eyes are recorded while they perform the task. In the visual search test, the same text is presented but all vowels are replaced by consonants. Participants must count in low voices the number of 'r' present in the text.
  2. Other parameters collected Sociodemographic data, personal and family psychiatric and somatic antecedents as well as previous and current treatments are collected.
Being tested
Methylphenidate Oral Tablet
Keywords
oculomotor performances, neurocognition, methylphenidate
Medical subject headings
Attention Deficit Disorder with Hyperactivity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Methylphenidate Oral TabletDrug

    Also called oculometry (eye tracking), neurocognition (TAP battery)

    cf arm group description

Study groups in NCT03411434
Study groupRoleWhat they receive
ADHD patientsExperimental90 patients will be enrolled and assessed (i.e., neurocognitive and oculomotor tests) at baseline ; after a single low dose of methylphenidate (10 mg orally); and after 6 months of adequate dose of methylphenidate oral tablet
Receives: Drug: Methylphenidate Oral Tablet

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in saccade latency after acute and chronic 6-month administration of methylphenidate vs. baseline

    Latency (time between the onset of the target and the beginning of the eye movements in milliseconds)

    Measured: Baseline (V0); methylphenidate test (V1; i.e., two weeks after V0, one hour after ingestion of a single low dose administration of MPH [10 mg orally given at 8 AM]); after 6 month's treatment with methylphenidate oral tablet (V2)

  2. Change in saccade average speed after acute and chronic 6-month administration of methylphenidate vs. baseline

    Average speed of the saccade (degree per second)

    Measured: Baseline (V0); methylphenidate test (V1; i.e., two weeks after V0, one hour after ingestion of a single low dose administration of MPH [10 mg orally given at 8 AM]); after 6 month's treatment with methylphenidate oral tablet (V2)

  3. Change in saccade accuracy after acute and chronic 6-month administration of methylphenidate vs. baseline

    Saccade accuracy (characterized by the ratio of the amplitude of the first saccade to the amplitude of the target, expressed in percentage)

    Measured: Baseline (V0); methylphenidate test (V1; i.e., two weeks after V0, one hour after ingestion of a single low dose administration of MPH [10 mg orally given at 8 AM]); after 6 month's treatment with methylphenidate oral tablet (V2)

  4. Change in direction errors after acute and chronic 6-month administration of methylphenidate vs. baseline

    Direction errors (in percentage)

    Measured: Baseline (V0); methylphenidate test (V1; i.e., two weeks after V0, one hour after ingestion of a single low dose administration of MPH [10 mg orally given at 8 AM]); after 6 month's treatment with methylphenidate oral tablet (V2)

  5. Change in anticipatory saccades after acute and chronic 6-month administration of methylphenidate vs. baseline

    Anticipatory saccades (saccade initiated < 80 msec after target appearance, in percentage)

    Measured: Baseline (V0); methylphenidate test (V1; i.e., two weeks after V0, one hour after ingestion of a single low dose administration of MPH [10 mg orally given at 8 AM]); after 6 month's treatment with methylphenidate oral tablet (V2)

  6. Change in express saccades after acute and chronic 6-month administration of methylphenidate vs. baseline

    Express saccades (reaction time between 80 and 130 msec, expressed in percentage).

    Measured: Baseline (V0); methylphenidate test (V1; i.e., two weeks after V0, one hour after ingestion of a single low dose administration of MPH [10 mg orally given at 8 AM]); after 6 month's treatment with methylphenidate oral tablet (V2)

Secondary outcomes (2)
  1. Associations between clinical outcome after 6 month's methylphenidate treatment and change in oculomotor performance (from V0 to V1, V0 to V2, and V1 to V2)

    Clinical Global Impression (CGI). The CGI is rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients). Global improvement or change (CGI-C) scores range from 1 (very much improved) through to 7 (very much worse). Treatment response ratings should take account of both therapeutic efficacy and treatment-related adverse events and range from 0 (marked improvement and no side-effects) and 4 (unchanged or worse and side-effects outweigh the thera- peutic effects). Each component of the CGI is rated separately; the instrument does not yield a global score.

    Measured: Baseline (V0); methylphenidate test (V1; i.e., two weeks after V0, one hour after ingestion of a single low dose administration of MPH [10 mg orally given at 8 AM]); after 6 month's treatment with methylphenidate oral tablet (V2)

  2. Associations between oculomotor data and neurocognitive test results

    computerized neurocognitive tests (KITAP for children up to 10 years; TAP for children above 11 years, adolescents, and adults)

    Measured: Baseline (V0); methylphenidate test (V1; i.e., two weeks after V0, one hour after ingestion of a single low dose administration of MPH [10 mg orally given at 8 AM]); after 6 month's treatment with methylphenidate oral tablet (V2)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Jan 2018
  2. Study start17 Feb 2014
  3. Primary completion31 Dec 2019 (estimated)
  4. Study completion31 Dec 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Model description
Interventional study designed to evaluate routine care. The patients are their own controls. Oculomotor and neurocognitive performances are assessed at baseline (V0), during the methylphenidate test (V1), and after 6 months of methylphenidate treatment
Masking
None (open label)
Enrolment
90 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03411434
Sponsor's protocol ID
AO-005/20131104
Status last verified
Jan 2018
First submitted
12 Jan 2018
Last updated
26 Jan 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Munoz DP, Armstrong IT, Hampton KA, Moore KD. Altered control of visual fixation and saccadic eye movements in attention-deficit hyperactivity disorder. J Neurophysiol. 2003 Jul;90(1):503-14. doi: 10.1152/jn.00192.2003. Epub 2003 Apr 2.

    PubMed 12672781
  • Kurscheidt JC, Peiler P, Behnken A, Abel S, Pedersen A, Suslow T, Deckert J. Acute effects of methylphenidate on neuropsychological parameters in adults with ADHD: possible relevance for therapy. J Neural Transm (Vienna). 2008;115(2):357-62. doi: 10.1007/s00702-008-0871-4. Epub 2008 Feb 12.

    PubMed 18264813
  • Duval F, Erb A, Mokrani MC, Weiss T, Carcangiu R. First-Dose Methylphenidate-Induced Changes in the Anti-Saccade Task Performance and Outcome in Adults with Attention-Deficit/Hyperactivity Disorder. Psychiatr Res Clin Pract. 2021 May 19;3(4):146-152. doi: 10.1176/appi.prcp.20210010. eCollection 2021 Winter.

    PubMed 36101656

Questions about this trial

What is this clinical trial studying?

A study testing Methylphenidate Oral Tablet in people with Attention Deficit Hyperactivity Disorder, run by Centre Hospitalier Rouffach at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 26 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Fabrice Duval, MD (33389787018, f.duval@ch-rouffach.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in saccade latency after acute and chronic 6-month administration of methylphenidate vs. baseline (time frame: Baseline (V0); methylphenidate test (V1; i.e., two weeks after V0, one hour after ingestion of a single low dose administration of MPH [10 mg orally given at 8 AM]); after 6 month's treatment with methylphenidate oral tablet (V2)). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03411434, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in